Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia

Aberrant expression of aurora kinase A is implicated in the genesis of various neoplasms, including acute myeloid leukemia. Alisertib, an aurora A kinase inhibitor, has demonstrated efficacy as monotherapy in trials of myeloid malignancy, and this efficacy appears enhanced in combination with conven...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Haematologica
Main Authors: Fathi, Amir T., Wander, Seth A., Blonquist, Traci M., Brunner, Andrew M., Amrein, Philip C., Supko, Jeffrey, Hermance, Nicole M., Manning, Amity L., Sadrzadeh, Hossein, Ballen, Karen K., Attar, Eyal C., Graubert, Timothy A., Hobbs, Gabriela, Joseph, Christelle, Perry, Ashley M., Burke, Meghan, Silver, Regina, Foster, Julia, Bergeron, Meghan, Ramos, Aura Y., Som, Tina T., Fishman, Kaitlyn M., McGregor, Kristin L., Connolly, Christine, Neuberg, Donna S., Chen, Yi-Bin
פורמט: Artigo
שפה:Inglês
יצא לאור: Ferrata Storti Foundation 2017
נושאים:
Articles
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5395112/
https://ncbi.nlm.nih.gov/pubmed/28034990
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2016.158394
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים